CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Tempest Therapeutics, Inc. - TPST CFD

    3.39
    2.87%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.06
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 3.49
    Open* 3.41
    1-Year Change* 122.88%
    Day's Range* 3.32 - 3.57
    52 wk Range 0.17-9.77
    Average Volume (10 days) 7.68M
    Average Volume (3 months) 223.53M
    Market Cap 74.30M
    P/E Ratio -100.00K
    Shares Outstanding 19.25M
    Revenue N/A
    EPS -2.24
    Dividend (Yield %) N/A
    Beta -1.24
    Next Earnings Date Mar 20, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 1, 2023 3.39 -0.05 -1.45% 3.44 3.58 3.31
    Nov 30, 2023 3.49 0.16 4.80% 3.33 3.58 3.31
    Nov 29, 2023 3.31 -0.37 -10.05% 3.68 3.79 3.31
    Nov 28, 2023 3.70 -0.06 -1.60% 3.76 4.06 3.59
    Nov 27, 2023 3.73 -0.04 -1.06% 3.77 3.92 3.59
    Nov 24, 2023 3.86 -0.24 -5.85% 4.10 4.32 3.84
    Nov 22, 2023 4.16 0.31 8.05% 3.85 4.39 3.83
    Nov 21, 2023 3.82 0.14 3.80% 3.68 3.82 3.55
    Nov 20, 2023 3.75 0.34 9.97% 3.41 3.90 3.29
    Nov 17, 2023 3.43 0.21 6.52% 3.22 3.56 3.19
    Nov 16, 2023 3.29 -0.02 -0.60% 3.31 3.33 3.14
    Nov 15, 2023 3.25 0.12 3.83% 3.13 3.48 3.10
    Nov 14, 2023 3.17 -0.31 -8.91% 3.48 3.53 3.10
    Nov 13, 2023 3.40 0.25 7.94% 3.15 3.72 3.13
    Nov 10, 2023 3.16 0.05 1.61% 3.11 3.33 2.83
    Nov 9, 2023 3.25 -0.18 -5.25% 3.43 4.30 3.14
    Nov 8, 2023 2.81 -0.19 -6.33% 3.00 3.06 2.73
    Nov 7, 2023 3.06 -0.02 -0.65% 3.08 3.28 2.79
    Nov 6, 2023 3.07 -0.61 -16.58% 3.68 3.68 2.95
    Nov 3, 2023 3.61 -0.27 -6.96% 3.88 3.92 3.58

    Tempest Therapeutics, Inc. Events

    Time (UTC) Country Event
    Wednesday, March 20, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q4 2023 Tempest Therapeutics Inc Earnings Release
    Q4 2023 Tempest Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Revenue
    Cost of Revenue, Total
    Gross Profit
    Total Operating Expense 34.64 26.986 35.972 45.399 26.874
    Selling/General/Admin. Expenses, Total 12.113 9.82 15.598 17.556 12.449
    Research & Development 22.527 17.166 20.374 27.843 14.425
    Unusual Expense (Income)
    Operating Income -34.64 -26.986 -35.972 -45.399 -26.874
    Interest Income (Expense), Net Non-Operating -1.618 -1.282 0.155 1.038 -0.343
    Other, Net 0.549 -0.034 -0.589 -0.207 0.04
    Net Income Before Taxes -35.709 -28.302 -36.406 -44.568 -27.177
    Net Income After Taxes -35.709 -28.302 -36.406 -44.568 -27.177
    Net Income Before Extra. Items -35.709 -28.302 -36.406 -44.568 -27.192
    Net Income -35.709 -28.302 -36.406 -44.568 -27.192
    Income Available to Common Excl. Extra. Items -35.709 -28.302 -36.406 -44.568 -27.192
    Income Available to Common Incl. Extra. Items -35.709 -28.302 -36.406 -44.568 -27.192
    Diluted Net Income -35.709 -28.302 -36.406 -44.568 -27.192
    Diluted Weighted Average Shares 11.5489 3.7903 1.25757 0.91383 0.10314
    Diluted EPS Excluding Extraordinary Items -3.09198 -7.46695 -28.9496 -48.7706 -263.637
    Diluted Normalized EPS -3.09198 -7.46695 -28.9496 -48.7706 -263.637
    Total Extraordinary Items
    Minority Interest 0 -0.015
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 7.47 7.581 8.934 8.771 8.774
    Selling/General/Admin. Expenses, Total 3.054 2.903 3.14 2.798 3.123
    Research & Development 4.416 4.678 5.794 5.973 5.651
    Operating Income -7.47 -7.581 -8.934 -8.771 -8.774
    Interest Income (Expense), Net Non-Operating -0.111 -0.055 -0.432 -0.176 -0.394
    Net Income Before Taxes -7.581 -7.636 -9.103 -8.947 -9.168
    Net Income After Taxes -7.581 -7.636 -9.103 -8.947 -9.168
    Net Income Before Extra. Items -7.581 -7.636 -9.103 -8.947 -9.168
    Net Income -7.581 -7.636 -9.103 -8.947 -9.168
    Income Available to Common Excl. Extra. Items -7.581 -7.636 -9.103 -8.947 -9.168
    Income Available to Common Incl. Extra. Items -7.581 -7.636 -9.103 -8.947 -9.168
    Diluted Net Income -7.581 -7.636 -9.103 -8.947 -9.168
    Diluted Weighted Average Shares 14.1022 13.7632 13.7479 13.6359 11.5734
    Diluted EPS Excluding Extraordinary Items -0.53758 -0.55481 -0.66214 -0.65613 -0.79216
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.53758 -0.55481 -0.66214 -0.65613 -0.79216
    Other, Net 0.263
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 32.95 68.963 40.901 71.132 83.422
    Cash and Short Term Investments 31.23 51.829 38.174 62.478 77.671
    Cash & Equivalents 31.23 51.829 38.174 62.478 73.286
    Short Term Investments 0 4.385
    Prepaid Expenses 1.007 1.581 1.929 6.344 3.373
    Other Current Assets, Total 0.713 15.553 0.484 1.034 0.045
    Total Assets 46.089 73.238 43.409 74.97 84.074
    Property/Plant/Equipment, Total - Net 12.71 4.164 2.157 3.331
    Property/Plant/Equipment, Total - Gross 14.071 4.988
    Accumulated Depreciation, Total -1.361 -0.824
    Long Term Investments
    Other Long Term Assets, Total 0.429 0.111 0.351 0.507 0.652
    Total Current Liabilities 7.277 20.026 7.987 12.52 9.817
    Accounts Payable 1.108 0.991 1.486 1.495 1.998
    Accrued Expenses 5.719 4.035 6.262 10.817 7.63
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 27.978 37.121 10.351 16.423 13.123
    Total Long Term Debt 10.371 15.069 0.061 0.168 0.383
    Other Liabilities, Total 10.33 2.026 1.635 2.411 0.752
    Total Equity 18.111 36.117 33.058 58.547 70.951
    Redeemable Preferred Stock 0 0 0 0
    Common Stock 0.011 0.007 0.019 0.018 0.013
    Additional Paid-In Capital 153.872 136.173 277.647 267.018 234.876
    Retained Earnings (Accumulated Deficit) -135.772 -100.063 -245.06 -208.654 -164.086
    Other Equity, Total 0.452 0.165 0.148
    Total Liabilities & Shareholders’ Equity 46.089 73.238 43.409 74.97 84.074
    Total Common Shares Outstanding 10.5185 6.91032 1.26671 1.21783 0.89058
    Total Receivables, Net 0.314 1.276 2.333
    Current Port. of LT Debt/Capital Leases 0.239 0.208 0.189
    Long Term Debt 10.371 15.069 0.061 0.168 0.383
    Minority Interest 0.668 1.324 2.171
    Other Current Liabilities, Total 0.45 15
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 12.291 18.535 24.673 32.95 60.257
    Cash and Short Term Investments 11.118 17.604 22.925 31.23 42.791
    Cash & Equivalents 11.118 17.604 22.925 31.23 42.791
    Short Term Investments
    Total Receivables, Net
    Prepaid Expenses 0.941 0.538 0.879 1.007 1.331
    Other Current Assets, Total 0.232 0.393 0.869 0.713 16.135
    Total Assets 23.987 30.742 37.329 46.089 63.171
    Property/Plant/Equipment, Total - Net 11.303 11.809 12.227 12.71 2.231
    Other Long Term Assets, Total 0.393 0.398 0.429 0.429 0.683
    Total Current Liabilities 7.422 8.638 7.511 7.277 24.059
    Accounts Payable 1.139 0.868 1.157 1.108 0.925
    Accrued Expenses 4.149 4.796 4.423 5.719 4.434
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 2.134 2.974 1.481 3.5
    Total Liabilities 25.177 25.73 26.364 27.978 36.398
    Total Long Term Debt 8.371 7.484 8.935 10.371 11.836
    Long Term Debt 8.371 7.484 8.935 10.371 11.836
    Minority Interest
    Other Liabilities, Total 9.384 9.608 9.918 10.33 0.503
    Total Equity -1.19 5.012 10.965 18.111 26.773
    Redeemable Preferred Stock
    Common Stock 0.014 0.013 0.011 0.011 0.01
    Additional Paid-In Capital 156.571 155.988 154.362 153.872 153.432
    Retained Earnings (Accumulated Deficit) -157.775 -150.989 -143.408 -135.772 -126.669
    Other Equity, Total
    Total Liabilities & Shareholders’ Equity 23.987 30.742 37.329 46.089 63.171
    Total Common Shares Outstanding 14.3234 12.5838 10.5617 10.5185 10.5171
    Property/Plant/Equipment, Total - Gross 12.955 13.374 13.714 14.071 3.476
    Accumulated Depreciation, Total -1.652 -1.565 -1.487 -1.361 -1.245
    Other Current Liabilities, Total 0 0 0.45 0.45 15.2
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -35.709 -28.302 -36.406 -44.568 -27.177
    Cash From Operating Activities -31.072 -25.957 -30.435 -41.222 -23.647
    Cash From Operating Activities 0.638 0.374 0.152 0.097 0.032
    Non-Cash Items 2.875 2.676 5.523 5.302 2.462
    Changes in Working Capital 1.124 -0.705 0.296 -2.053 1.036
    Cash From Investing Activities -0.562 -0.097 -0.026 3.988 1.932
    Capital Expenditures -0.562 -0.135 -0.026 -0.397 -0.036
    Other Investing Cash Flow Items, Total 0 0.038 0 4.385 1.968
    Cash From Financing Activities 11.403 59.063 5.386 26.943 77.744
    Issuance (Retirement) of Stock, Net 16.142 33.533 5.531 27.145 38.756
    Net Change in Cash -20.231 33.009 -24.854 -10.258 56.147
    Financing Cash Flow Items 0 10.53 0 31.157
    Issuance (Retirement) of Debt, Net -4.739 15 -0.145 -0.202 7.831
    Foreign Exchange Effects 0.221 0.033 0.118
    Cash Taxes Paid 0.018 0
    Cash Interest Paid 1.539 0.953
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -7.636 -35.709 -26.606 -17.659 -8.491
    Cash From Operating Activities -8.303 -31.072 -24.593 -15.521 -7.107
    Cash From Operating Activities 0.125 0.638 0.421 0.22 0.108
    Non-Cash Items 0.938 2.875 2.281 1.549 0.705
    Cash Interest Paid 0.292 1.539 0.893 0.556 0.268
    Changes in Working Capital -1.73 1.124 -0.689 0.369 0.571
    Cash From Investing Activities -0.046 -0.562 -0.206 -0.098 -0.003
    Capital Expenditures -0.046 -0.562 -0.206 -0.098 -0.003
    Cash From Financing Activities 0.044 11.403 16.129 15.779 1.403
    Financing Cash Flow Items 0 0 0 0
    Issuance (Retirement) of Stock, Net 0.044 16.142 16.129 15.779 1.403
    Issuance (Retirement) of Debt, Net -4.739 0 0 0
    Net Change in Cash -8.305 -20.231 -8.67 0.16 -5.707
    Other Investing Cash Flow Items, Total 0 0
    Foreign Exchange Effects 0
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Versant Ventures Venture Capital 32.2353 4295055 3123961 2022-04-29 LOW
    EcoR1 Capital, LLC Hedge Fund 8.4316 1123434 92166 2023-06-30 LOW
    Fidelity Management & Research Company LLC Investment Advisor 4.8626 647898 0 2023-06-30 LOW
    Maples Corporate Services Ltd Investment Advisor 4.3508 579710 579710 2023-03-01 HIGH
    Rock Springs Capital Management LP Hedge Fund 4.0244 536214 -287440 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.3254 309840 59889 2023-06-30 LOW
    AIGH Capital Management, LLC. Private Equity 2.2868 304700 304700 2023-06-30 MED
    Sectoral Asset Management Inc. Investment Advisor/Hedge Fund 1.6466 219394 119394 2023-06-30 MED
    Fidelity International Investment Advisor 0.9725 129579 0 2023-06-30 LOW
    Dubensky (Thomas W) Individual Investor 0.8507 113343 0 2023-03-01 LOW
    Renaissance Technologies LLC Hedge Fund 0.776 103401 76901 2023-06-30 HIGH
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.7674 102244 35372 2023-06-30 LOW
    Worth Venture Partners, LLC Investment Advisor/Hedge Fund 0.7622 101550 101550 2023-06-30 HIGH
    BlackRock Institutional Trust Company, N.A. Investment Advisor 0.6235 83073 0 2023-06-30 LOW
    Two Sigma Investments, LP Hedge Fund 0.2291 30532 30532 2023-06-30 HIGH
    Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.1017 13553 0 2023-06-30 LOW
    Millennium Management LLC Hedge Fund 0.0775 10331 -6466 2023-06-30 HIGH
    Tower Research Capital LLC Hedge Fund 0.0652 8681 32 2023-06-30 HIGH
    Whiting (Samuel) Individual Investor 0.0368 4901 3000 2023-03-01 LOW
    Brady (Stephen R) Individual Investor 0.0225 3000 3000 2023-03-01

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Tempest Therapeutics, Inc. Company profile

    About Tempest Therapeutics Inc

    Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.

    Financial summary

    BRIEF: For the nine months ended 30 September 2021, Tempest Therapeutics Inc revenues was not reported. Net loss decreased 29% to $20.5M. Lower net loss reflects Research and development - Balancing decrease of 23% to $12.2M (expense), Other general and administrative decrease of 32% to $6.6M (expense), Stock-based Compensation in SGA decrease of 75% to $600K (expense).

    Equity composition

    Common Stock $.001 par, 11/12, 100M auth., 14,262,276 issd., Insider Own approx.1%.

    Industry: Biotechnology & Medical Research (NEC)

    2000 Sierra Point Parkway
    Suite 400
    BRISBANE
    CALIFORNIA 94005
    US

    Income Statement

    • Annual
    • Quarterly

    News

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    People also watch

    Gold

    2,072.25 Price
    +1.760% 1D Chg, %
    Long position overnight fee -0.0193%
    Short position overnight fee 0.0111%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    XRP/USD

    0.63 Price
    -0.220% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    BTC/USD

    39,809.25 Price
    +0.450% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    US100

    16,001.20 Price
    +0.470% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading